Squarex unveils Phase 2 results of SQX770 in recurrent herpes labialis
Category: #health  By Mateen Dalal  Date: 2019-08-06
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Squarex unveils Phase 2 results of SQX770 in recurrent herpes labialis

The study involved around 139 subjects who had reported four or more episodes of herpes labialis in the past 12 months

Squarex, a clinical-stage pharmaceutical company has reportedly unveiled the positive results from a Phase 2 clinical trial of its investigational compound, SQX770, which is a tropical formulation of the immunomodulator squaric acid dibutyl ester, in patients with oral herpes.

Apparently, the company aims to initiate a Phase 3 study after a planned FDA end of Phase 2 clinical meeting later in the year.

Sources close to the matter informed that the placebo-controlled, multi-center, double-blinded randomized Phase 2 study involved around 139 subjects who had reported four or more episodes of herpes labialis in the past 12 months. The study was formally designed to ascertain if the topical application of SADBE is able to delay HSV-1 outbreaks.

Seemingly, results from the Phase 2 clinical trial defined that a single topical dosage of SQX770 applied to the upper arm substantially extended time to subsequent herpes labialis outbreak and reduced both the severity and frequency of outbreaks. The greatest effect was registered during days 43 to 121 following the application of drug. These findings indicate SQX770 immunotherapy can take up to 6 weeks to completely exert a clinically significant effect on the immune system.

Sources further stated that no serious adverse events were reported so far. The adverse events that were officially reported, like local reaction owing to the sensitization and challenge responses on the skin, were what investigators anticipated to witness using a topical immunomodulator.

According to Jack Talley, Chief Executive Officer of Squarex, the company’s findings confirm and validate the results from two former studies including a prior placebo controlled clinical trial and therefore, open the way for the initiation of a Phase 3 clinical trial. With no existing preventative treatment options available on the market for the millions of patients who are suffering from recurrent HSV-1 outbreaks, Squarex is ready to continue the clinical development and could expectedly bring the first and only option for combating herpes labialis.

Source Credits: https://www.prnewswire.com/news-releases/squarex-announces-positive-results-from-completed-phase-2-study-of-sqx770-in-the-prevention-of-recurrent-herpes-labialis-300896065.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

By Mateen Dalal

The two companies intend to introduce their custom-made sub-6GHz 5G chipsets by the end of 2021. UNISOC has managed to raise around USD 817.20 million for its new venture. Chinese electronics giants including Xiaomi Corp. and Guangdong Oppo Mob...

Twitter explored USD 4 billion takeover of audio-chat app Clubhouse

Twitter explored USD 4 billion takeover of audio-chat app Clubhouse

By Mateen Dalal

Twitter, an American microblogging service company, had touted plans of acquiring Clubhouse, an audio chat iPhone app and live drop-in audio networking platform. The deal was estimated to be valued at around USD 4 billion, as per reliable sources. T...

Beyond Meat sets up factory in China to expedite localized innovation

Beyond Meat sets up factory in China to expedite localized innovation

By Mateen Dalal

American plant-based meat substitute producer Beyond Meat has opened a new production facility in China. Apparently, this recent setup is the company’s first facility outside the U.S., making it the only multinational organization solely focusi...